AVT-80 (vedolizumab biosimilar)
/ Alvotech
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
September 25, 2025
AVT80-GL-P01: Study to Investigate Comparative Pharmacokinetics, Safety, Immunogenicity and Tolerability Between AVT80 and Entyvio
(clinicaltrials.gov)
- P1 | N=351 | Active, not recruiting | Sponsor: Alvotech Swiss AG | Trial completion date: Oct 2025 ➔ Jan 2026 | Trial primary completion date: Oct 2025 ➔ Jan 2026
Trial completion date • Trial primary completion date
September 17, 2025
AVT80-GL-P01: Study to Investigate Comparative Pharmacokinetics, Safety, Immunogenicity and Tolerability Between AVT80 and Entyvio
(clinicaltrials.gov)
- P1 | N=351 | Active, not recruiting | Sponsor: Alvotech Swiss AG | Recruiting ➔ Active, not recruiting
Enrollment closed
February 12, 2025
AVT80-GL-P01: Study to Investigate Comparative Pharmacokinetics, Safety, Immunogenicity and Tolerability Between AVT80 and Entyvio
(clinicaltrials.gov)
- P1 | N=351 | Recruiting | Sponsor: Alvotech Swiss AG | Not yet recruiting ➔ Recruiting
Enrollment open
December 13, 2024
AVT80-GL-P01: Study to Investigate Comparative Pharmacokinetics, Safety, Immunogenicity and Tolerability Between AVT80 and Entyvio
(clinicaltrials.gov)
- P1 | N=351 | Not yet recruiting | Sponsor: Alvotech Swiss AG
New P1 trial
1 to 4
Of
4
Go to page
1